TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: HIP: HIV Intervention for Providers
Brief Summary: The purpose is to encourage Provider participants to evaluate high risk HIV transmission behaviors and offer prevention messages to their HIV+ patients which will, in turn, reduce rates of unprotected anal and/or vaginal sex with partners of known HIV sero-negativity or unknown HIV serostatus. It is hypothesized that patients of providers participating in the HIP intervention will report higher reduction in sexual risk practices, when compared to the patients of the providers who were randomized into the control condition.


Options:
A: Inclusion Criteria:

Home-dwelling patients aged 65 or higher, who have a diagnosis of depression, according to International Statistical Classification of Diseases and Related Health Problems, Tenth Revision

Exclusion Criteria:

Patients will be excluded if they have a diagnosis of dementia, bipolar disorder or reside in nursing homes or is assessed by their practitioner to have low life expectancy.
B: Inclusion Criteria:

* LTC homes in Ontario that are serviced by MPGI
C: Inclusion Criteria:

* the patient (or their caregiver) reports that the patient is suffering from a fever or has a history of fever in this illness episode
* the patient is present at the health facility

Exclusion Criteria:

* the patient is pregnant
* the patient is \<6 months old
* the patient has signs or symptoms of severe malaria
D: Inclusion Criteria:

* Provider participants: (1) licensed MD, NP or PA on staff at the participating institution; (2) has a minimum panel of 5 HIV+ patients; (3) sees patients at least one-half day per week in the clinical setting; (4) is willing to participate in all intervention training sessions; and (5) is willing and able to provide full informed consent.

HIV+ patient participants:(1) report at least 1 encounter of unprotected anal or vaginal sex with known HIV- or unknown serostatus partner in the preceding six months; (2) patient's Primary Provider is enrolled as a participant in the study; (3) age 18 years or older; and (4) willing and able to provide informed consent.

Exclusion Criteria:

-

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Evaluating Tools for Health Promotion and Disease Prevention
Brief Summary: The study will evaluate the effect of familial risk assessment and prevention prompts tailored to familial risk on health behaviors and use of preventive services among adults who are members of primary care practices in the U.S.


Options:
A: Inclusion Criteria:

* Chinese American women had not had a mammography in the past 12 months
* Chinese American women had no personal history of breast cancer
* Chinese American women had no mammogram scheduled when enrolled

Exclusion Criteria:

* Non-Chinese Women
* Regular mammography users
B: Inclusion Criteria:

* member of participating primary care practice network
* able to provide informed consent
* able to complete data assessment tools in English

Exclusion Criteria:

* diagnosis of CHD, stroke, diabetes, breast cancer, ovarian cancer, or colorectal cancer
* currently pregnant
* evidence of cognitive impairment
C: Inclusion Criteria:

For Physicians

1. are Chinese American,
2. practice primary care,
3. have a least 75 Chinese patients aged 50 and older in their practice,
4. can communicate with patients in Chinese (Mandarin, Cantonese, etc.)

For Patients

1. visiting the participating physician at least once in the past 2 years,
2. are Chinese Americans,
3. are 50 years and older,
4. never had any CRC screening or are overdue for screening.

Exclusion Criteria:

For Patients:

1. have a colorectal polyp, CRC cancer, or a family history of CRC (first degree relative), and
2. had updated CRC screening (FOBT within one year, colonoscopy within 10 years, sigmoidoscopy within 5 years and double-contrast barium enema within 5 years).
D: Inclusion criteria:

* Diagnosis of low back pain including lumbago, unspecified backache, sprains and strains of sacroiliac, lumbar, sacral, or unspecified regions of the spine
* Back pain must be of at least 3 months duration and rated at least 3 on a symptom bothersomeness scale

Exclusion criteria:

* non-mechanical causes or potential causes of low back pain (i.e. sciatica, underlying systemic or visceral disease, pregnancy, spondylolisthesis, spinal stenosis, cancer or unexplained weight loss, recent vertebral fracture)
* previous treatment with acupuncture
* inappropriate candidate for acupuncture (i.e. severe clotting disorders or on anticoagulant medication, heart pacemakers)
* characteristics complicating the interpretation of the findings (severe or progressive neurologic deficits, back surgery within the prior three years, planning to seek other treatment for back pain)
* characteristics related to ability to complete the study protocol (unable to speak English, plans to move out of town)

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Legacy for Children, The CDC Parenting Research Projects
Brief Summary: The purpose of this study is to determine if an intervention focused on promoting parent-child interaction, parental responsibility, parental commitment of time and energy, and sense of community results in better developmental outcomes for low-income children.


Options:
A: Inclusion Criteria:

* child 2 to 5 years old
* parent reports reason for referral is child behavior problems
* parent is a biological or adoptive parent, or legal guardian of child

Exclusion Criteria:

* parent is psychotic or actively abusing substances
* child is autistic or severely developmentally delayed
B: Inclusion Criteria:

Parent or primary caregiver of a child who fits the following criteria:

* Receives a positive result on behavioral screening

Exclusion Criteria:

Parent or primary caregiver of a child who fits the following criteria:

* Diagnosis of pervasive developmental disorder or global developmental delay
C: Inclusion Criteria:

-Parents, mothers as well as their partners, expecting their first child in the municipality of Aarhus are eligible for the study. This is because of the universal nature of the original program. Mothers are included if interested regardless of the fathers' decline. Biological fathers, registered partners, as well as non-registered partners are eligible.

Exclusion Criteria:

* Parents are excluded from the study if they are under the age of 18 years
* Not capable of managing own legal affairs
* Choose not to accept any routine pregnancy scans. These exclusion criteria are chosen to secure that study participants are legally responsible and that we are able to recruit them via the Department of Obstetrics and Gynaecology in connection with the nuchal translucency scan around week 12
* The father or partner is not included if the mother declines participation. The mother can choose to attend the Family Startup Program with a friend (i.e. a sister, friend or neighbor) but friends are not eligible for the study
* Finally, individuals are excluded if they are not able to understand the Danish oral presentation of the study information and hence cannot give informed consent
D: Inclusion Criteria:

* English speaking
* Live within 10 miles of UCLA
* 18 years of age or older
* Receive their prenatal and well-baby care from MediCal
* Live within 50 minutes of the three community intervention sites
* Reside within zip codes corresponding to the lowest performing schools in the broad Miami area
* Give birth to the target child at participating hospitals

Exclusion Criteria:

* Multiple birth greater than twins
* Existing Substance abuse
* Existing Mental Health issues

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Administration of Intravenous Proton Pump Inhibitor Prior to Endoscopy [APPE] in Patients With Upper Gastrointestinal Bleeding; a Double-Blind Placebo-Controlled Randomised Study.
Brief Summary: To evaluate if intravenous PPI infusion, when administered prior to endoscopy, hastens resolution of bleeding stigmata and thereby facilitates endoscopic examinations and reduces the need for endoscopic treatment. Clot stabilization may itself sustain control of bleeding before endoscopy. These may translate into improved patients'outcome and survival.

To determine the therapeutic effect of high-dose PPI infusion in upper gastrointestinal bleeding from causes other than peptic ulcers.


Options:
A: Inclusion Criteria:

* Signs of a bleeding in the stomach
* One endoscopically confirmed bleeding ulcer in the stomach or duodenum

Exclusion Criteria:

* Malignancy or other advanced disease.
* Major cardiovascular event.
* Severe hepatic disease
B: Inclusion Criteria:

* A peptic ulcer with active bleeding,a non-bleeding visible vessel (NBVV) or an adherent blood clot at the ulcer base is observed within 24 hours of hospital admission

Exclusion Criteria:

* Patients are excluded from the study if they are pregnant,
* Do not obtain initial hemostasis with endoscopic injection of epinephrine
* Do not give written informed consent
* Have bleeding tendency (platelet count \<50×109/L,serum prothrombin \<30% of normal,or were taking anticoagulants)
* Uremia.
C: Inclusion Criteria:

* Patients with overt signs of upper GIB; fresh hematemesis and/or melena with or with circulatory compromise

Exclusion Criteria:

* Chronic aspirin user,
* Pregnancy,
* Age\<16,
* Allergy to PPI,
* No consent
D: Inclusion Criteria:

* Patients who received gastroscopy for melena, hematochezia, or hematemesis in whom bleeding peptic ulcers with major stigmata of recent hemorrhage are detected are consecutively enrolled. All of these major SRH are treated by local injection of diluted epinephrine 1:10000 with or without combined therapy with a heater probe, argon plasma coagulation, band ligation, or hemoclip therapy.

Exclusion Criteria:

* Patients are excluded if they had tumor bleeding or ulcer bleeding due to mechanical factors (i.e., gastrostomy tube induction), warfarin use, failure to establish hemostasis under gastroscopy, or hypersensitivity to esomeprazole or any component of the formulation.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Parent-Youth Teamwork in Pediatric Asthma Management
Brief Summary: The purpose of this research study is to examine the effectiveness of a parent-youth teamwork treatment and an asthma education treatment in helping children use their asthma medicines correctly. We also want to learn about how these treatments affect parental involvement in asthma care, parent and youth relationships, and children's health care.


Options:
A: Inclusion Criteria:

1. age between 13-18 years
2. mild, moderate or severe persistent asthma specified by the NHLBI Asthma guidelines
3. asthma diagnosis \> 1 year
4. no other major chronic/emotional health concerns
5. ability to understand spoken and written English. Participants were recruited from the communities through flyers, newspaper ads, and referrals from clinics and schools.

Eligibility criteria for peer leaders included:

1. age between 16-20 years
2. nomination from school teachers/nurses or health care providers
3. average grade point B or above in the past school year
4. fulfillment of eligibility criteria (2)-(5) prescribed for adolescent participants.

Exclusion Criteria:

* learning disabilities based on reports from parents, teachers or clinicians
B: Inclusion Criteria:

* Adults step two therapy (BTS)
* Evidence of poorly controlled disease

Exclusion Criteria:

* Unable to benefit from self management education
* Other respiratory conditions other than asthma
C: Inclusion Criteria:

* patient has been diagnosed with asthma for at least 6 months
* patient can be managed appropriately on study medications as determined by the attending physician

Exclusion Criteria:

* patient shows evidence of neurological or significant cognitive impairment
D: Inclusion Criteria:

* Puerto Rican
* In high school
* Have asthma

Exclusion Criteria:

* More than 18 years old
* In last year of school
* Mild intermittent or controlled asthma

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Parent-Youth Teamwork in Pediatric Asthma Management
Brief Summary: The purpose of this research study is to examine the effectiveness of a parent-youth teamwork treatment and an asthma education treatment in helping children use their asthma medicines correctly. We also want to learn about how these treatments affect parental involvement in asthma care, parent and youth relationships, and children's health care.


Options:
A: Inclusion Criteria:

* 3-12 year old children with asthma requiring daily corticosteroid

Exclusion Criteria:

* sibling already in study
* physician excludes from participation
* non English Speaking
B: Inclusion Criteria:

* patient has been diagnosed with asthma for at least 6 months
* patient can be managed appropriately on study medications as determined by the attending physician

Exclusion Criteria:

* patient shows evidence of neurological or significant cognitive impairment
C: Inclusion Criteria:

* Doctor diagnosed asthma.
* On at least BTS stage 2, which means they will be on regular inhaled steroids.
* No change in regular asthma treatment in the last 1 month (on regular inhaled steroids, no change in steroid dose for

  1 month, no change in add on therapy in the last month).
* ACQ (Asthma Control Questionnaire) score more than or equal to 1.5.
* Can speak and understand English.

Exclusion Criteria:

* BTS stage 5 asthma (complex issues, too unstable).
* Recent changes to asthma treatment within the last month. (see above)
* ACQ (Asthma Control Questionnaire) score \< 1.5.
* Another chronic health condition (eg diabetes, congenital heart disease, cystic fibrosis).
* Can't speak or understand English.
D: Inclusion criteria:

* Diagnosed with persistent asthma.
* Not treated with the combination of a ICS (inhaled corticosteroid)and a LABA (long-acting beta-agonist).
* Female subjects must not be fertile or must use effective contraception.
* Subject must be able to comply with the use of the questionnaires in the local language.

Exclusion criteria:

* Known or suspected Chronic Obstructive Pulmonary Disease.
* Pregnant or lactating.
* Participating investigator, employee of an investigator, or family member of any of the aforementioned.
* Smoking history: Pack-years \> 10 years.
* Have known clinical or laboratory evidence of a serious uncontrolled systemic disease.
* Known hypersensitivity to any substance contained in investigational product or as-needed medication.
* Treatment with oral corticosteroid within 2 months prior to the screening visit.
* Upper or lower respiratory tract infection (microbiologically verified) within 1 month prior to screening visit.
* Acute asthma exacerbation requiring hospitalisation or emergency room treatment within 3 months prior to the screening visit.

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Rehabilitation, Brain Function and Early Schizophrenia
Brief Summary: This study will determine the effectiveness of cognitive enhancement therapy (CET) in treating cognitive abnormalities in people experiencing the early stages of schizophrenia.


Options:
A: Inclusion Criteria:

* DSM-IV-diagnosis of schizophrenia or schizoaffective disorder at any stage of illness

Exclusion Criteria:

* Unstable assignment (at least 3 months) to an ACT team;
* Prior exposure to SST or CBT in the past 5 years
* Level of care required interferes with outpatient therapy (e.g., current hospitalization for psychiatric, substance use or physical illness).
B: Inclusion Criteria:

* Outpatients
* Diagnosis of bipolar disorder type I or II, according to DSM-IV-TR 4ª Ed criteria
* Adult patients, aged between 18 and 55 years old
* Euthymic (YMRS \< 6, HDRS \< 8) for at least three months prior to study entry.
* Signed inform consent
* Severe or moderate functional impairment (FAST \> 18)

Exclusion Criteria:

* IQ \< 85
* Neurological illness
* Present diagnosis of substance abuse or dependence according to DSM-IV criteria the last three months
* Significant medical illness considered as severe by the study that may interfere with assessments
* having been enrolled in any kind of cognitive rehabilitation intervention the last two years
C: Inclusion Criteria:

* pscychotic illness of at least a years duration
* unemployed for at least a year

Exclusion Criteria:

-
D: Inclusion Criteria:

* DSM-IV diagnosis of schizophrenia, schizoaffective or schizophreniform disorder at the time of initial assessment
* Pre-treatment illness duration an average of 5 years, not to exceed 8 years
* Stable positive symptoms (e.g., if present do not grossly interfere with behavior such as command hallucinations or delusions)
* Currently maintained and compliant with prescribed antipsychotic medication
* Socially and cognitively disabled, e.g., meet criteria on a Cognitive Style Scale (score greater than or equal to 7), and Social Cognition Disability Scale (score greater than or equal to 12).

Exclusion Criteria:

* Alcohol/drug abuse or dependence that has significantly interfered with adjustment in the past two months (e.g., patients currently undergoing D and A treatment must successfully complete their recovery program prior to referral)
* Organic brain syndrome, including HIV illness (due to its effect on CNS function)
* IQ below 80 or language skills below the sixth grade level
* Medical contraindications that preclude an appropriate antipsychotic medication
* Persistent suicidality

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized Trial of Hydrocortisone in Very Preterm Infants at High Risk for Neurologic and Pulmonary Impairments
Brief Summary: The purpose of this study is to determine whether treatment of very preterm infants at high-risk for lung and brain injury with low dose hydrocortisone results in improved pulmonary and neurologic outcomes.


Options:
A: Inclusion Criteria:

* infants \<30 weeks estimated gestational age
* inborn at an NRN site or were admitted to an NRN site before 72 hours postnatal age
* have received at least 7days of mechanical ventilation;
* are receiving mechanical ventilation through an endotracheal tube .

Exclusion Criteria:

* Major congenital anomalies
* Decision to limit support
* Indomethacin or ibuprofen treatment within 48 hours of study drug
* Previous corticosteroid treatment for BPD
* Received hydrocortisone for 14 or more cumulative days
* Received hydrocortisone within 7 days of study entry
B: Inclusion Criteria:

* Gestational age between 24 weeks and 27 weeks + 6 days
* Babies born to mother with either clinical chorioamnionitis, preterm and prelabor rupture of the membranes (PPROM), or preterm labor
* Written informed consent obtained before inclusion and randomization.

Exclusion Criteria:

* Babies born to mothers with birth weight below the 3th percentile
* PPROM before 22 weeks
* Major fetal anomaly or congenital malformation
* Mother refusal or inability to provide consent.
C: Inclusion Criteria:

* Inborn infants
* 23 0/7 to 26 6/7 weeks estimated gestational age
* Umbilical arterial catheter in place at study entry
* \<= 24 hours of age

Exclusion Criteria:

* Terminally ill infants
* Infants that have received (prior to enrollment): \>20 ml/kg in fluid boluses, indomethacin, or ibuprofen
* Infants with major congenital anomalies
D: Inclusion Criteria:

* Patient in the Memorial Hermann Children's Hospital (MHCH) neonatal intensive care unit with a birth weight ≤ 1000 grams.
* Ventilator-dependent between 10 and 21 days of age.
* Respiratory index score (RIS: mean airway pressure x fraction of inspired oxygen) of ≥ 2.0 that is increasing or stable for the previous 24 hours or a RIS ≥ 3.0 if improvement noted in the past 24 hours.

Exclusion Criteria:

* Prior postnatal steroid treatment.
* Evidence of sepsis or necrotizing enterocolitis.
* Known major congenital anomalies of the cardiopulmonary or central nervous system.
* Infants being treated with indomethacin or those likely to require treatment in the next 7 days as judged by the treating physician.
* Inability or unwillingness of parent or legal guardian/representative to give written informed consent.
* Gestational age \< 23 weeks.

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota (NAMI): Pre-, Peri- and Postnatal Programming and Origins of Disease: Early Targeting the Epidemics of Allergy and Overweight
Brief Summary: Combined programme: Nutrition, Allergy, Mucosal immunology and Intestinal microbiota (NAMI) was created with the objective to reverse the rising trend of chronic inflammatory diseases, such as allergic disease and obesity, by control of the internal and external environments of the infant. To approach this problem, the project aims to characterize

* how immunology is regulated during pregnancy and early infancy,
* how the immune interaction between mother and child is influenced by nutritional and microbial factors, and
* how the regulation is related to disease risk.


Options:
A: Inclusion Criteria:

* Pregnant women from families with at least one family member having an allergic disease

Exclusion Criteria:

* Women presenting severe immunological or other chronic diseases (rheumatoid arthritis, diabetes, inflammatory bowel disease, thyroid diseases, malignancies etc.)
* Women who cannot be expected to comply with treatment
* Women currently participating or having participated in other clinical trial during the last 2 months prior to the beginning of the intervention.
B: Inclusion Criteria:

* Healthy infants.
* Infants 1 -3 months of age at the beginning of the study.
* Parents/guardians of each subject are able to understand study procedures and agree to participate in the study by giving consent.
* Parents and child are planning to remain in Dhaka for the next four months.

Exclusion Criteria:

* Infants with known birth defects.
* Infants who have been hospitalized.
* Infants who have an acute infection or illness at the time of enrolment.
* Infants who are currently taking antibiotics
* Infants \<1 month of age or \>3 months of age.
* Infants three standard deviations below mean on anthropometric measures (will be referred for medical care).
* Infants who are already receiving a probiotic product or treatment.
* A diagnosis or suspicion of immunodeficiency disorder.
* A diagnosis or suspicion of bleeding disorder that would contraindicate venipuncture.
* Family residence outside of Dhaka or families expecting to move outside of Dhaka in the next 4 months.
C: Inclusion Criteria:

* Full-term infants age \<5 months
* Infantile colic (\>3 hours of crying on \>3 days in the week) within 7 days prior to enrollment
* Exclusive or predominant (\>50%) breastfeeding
* Informed consent

Exclusion Criteria:

* Acute or chronic illness
* Gastrointestinal disorders
* Use of any antibiotics and/or probiotic pharmaceutical products within 7 days prior to the study.
D: Inclusion Criteria:

* neonates of 37-42 week gestational age and appropriate birth weight
* Recruitment age: until 7 days of life
* Informed consent signed

Exclusion Criteria:

* Presence of other gastrointestinal diseases.
* Use of FANS, aspirin or other drugs
* Use of antibiotics and/or PPIs e/o anti-H2
* Participation to other clinical trials

Answer: A